Medicare AdvantageCoverageMedium impact
Hematopoietic Stem Cell Transplantation - Medicare Advantage (Revised)
Humana·Hematology, Oncology, Transplant Surgery +2 more·Pharmacy
Effective date
Oct 1, 2026
We identified it
Oct 2, 2026
Summary
Humana Medicare Advantage has updated its Hematopoietic Stem Cell Transplantation policy (HUM-1017-004), effective October 1, 2026. The policy consolidates coverage criteria for allogeneic and autologous stem cell transplants, references multiple MAC-specific LCDs by geographic jurisdiction, and clarifies that Humana applies CMS NCD 110.23 standards while supplementing with additional evidence-based medical necessity criteria for jurisdictions without specific LCDs.
Action Required
By September 1, 2026: Billing and utilization management teams must review this updated policy and verify that all stem cell transplant claim submissions align with the applicable MAC LCD for their geographic jurisdiction (J5, J8, J6, JK, J15, JE, JF, JJ, or JM). Update internal policy references and prior authorization templates to reflect the new effective date. Confirm that billing software correctly routes allogeneic HSCT claims for lymphoma cases to the appropriate MAC LCD (L39477, L39513, L39434, L39396, or L39270 depending on jurisdiction). Train billing staff to identify medical necessity documentation requirements for CPT codes 38205, 38206, 38230, 38232, 38240, and 38241. For jurisdictions without specific LCDs (JH/JL, JN), ensure that utilization review processes reference the supplemental medical necessity criteria outlined in this policy. Failure to apply the correct MAC LCD may result in claim denials or delays.